DK1592384T3 - Cop 1 til behandling af inflammatoriske tarmsygdomme - Google Patents

Cop 1 til behandling af inflammatoriske tarmsygdomme

Info

Publication number
DK1592384T3
DK1592384T3 DK04703462.4T DK04703462T DK1592384T3 DK 1592384 T3 DK1592384 T3 DK 1592384T3 DK 04703462 T DK04703462 T DK 04703462T DK 1592384 T3 DK1592384 T3 DK 1592384T3
Authority
DK
Denmark
Prior art keywords
cop
treatment
inflammatory bowel
bowel diseases
diseases
Prior art date
Application number
DK04703462.4T
Other languages
English (en)
Inventor
Rina Aharoni
Ruth Arnon
Basak Kayhan
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK1592384T3 publication Critical patent/DK1592384T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04703462.4T 2003-01-21 2004-01-20 Cop 1 til behandling af inflammatoriske tarmsygdomme DK1592384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44113603P 2003-01-21 2003-01-21
PCT/IL2004/000054 WO2004064717A2 (en) 2003-01-21 2004-01-20 Cop 1 for treatment of inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
DK1592384T3 true DK1592384T3 (da) 2012-12-17

Family

ID=32771907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04703462.4T DK1592384T3 (da) 2003-01-21 2004-01-20 Cop 1 til behandling af inflammatoriske tarmsygdomme

Country Status (14)

Country Link
US (1) US8008258B2 (da)
EP (1) EP1592384B1 (da)
AU (1) AU2004206120B2 (da)
CA (1) CA2513567C (da)
DK (1) DK1592384T3 (da)
ES (1) ES2397836T3 (da)
MX (1) MXPA05007711A (da)
NO (1) NO333579B1 (da)
NZ (1) NZ569331A (da)
PT (1) PT1592384E (da)
RU (1) RU2339397C2 (da)
SI (1) SI1592384T1 (da)
WO (1) WO2004064717A2 (da)
ZA (1) ZA200505733B (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1459065B1 (en) * 2001-12-04 2010-07-28 Teva Pharmaceutical Industries, Ltd. Processes for the measurement of the potency of glatiramer acetate
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060172942A1 (en) * 2005-02-02 2006-08-03 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2732228A1 (en) * 2008-07-25 2010-01-28 The Johns Hopkins University Methods and compositions for treating and preventing autoimmune diseases
RS55607B1 (sr) 2009-08-20 2017-06-30 Yeda Research & Development Company Ltd Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
PL2598165T3 (pl) * 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2014058976A2 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN106456740B (zh) 2014-05-02 2021-06-08 Qu生物制药公司 抗微生物免疫调节
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3478300B1 (en) 2016-06-30 2022-08-24 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis with adipose-derived stem cells
EP3624815A4 (en) 2017-05-15 2021-01-20 Stem Cell Medicine Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206073A (pt) * 1991-05-31 1994-12-06 Pfizer Derivados de quinuclidina
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en) * 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2408706T3 (es) 1998-09-25 2013-06-21 Yeda Research And Development Co., Ltd. Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico
WO2000020010A1 (en) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) * 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US20010044416A1 (en) * 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
AU2003204344A1 (en) * 2002-05-23 2003-12-11 Milder, Dan George Compositions and methods for the treatment of autoimmune diseases and neurological disorders
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene

Also Published As

Publication number Publication date
US8008258B2 (en) 2011-08-30
AU2004206120A1 (en) 2004-08-05
CA2513567A1 (en) 2004-08-05
SI1592384T1 (sl) 2013-03-29
NO333579B1 (no) 2013-07-15
WO2004064717A3 (en) 2005-10-13
RU2005126412A (ru) 2006-01-27
NO20053860L (no) 2005-10-20
ZA200505733B (en) 2006-10-25
CA2513567C (en) 2012-10-23
NZ569331A (en) 2010-08-27
NO20053860D0 (no) 2005-08-18
RU2339397C2 (ru) 2008-11-27
MXPA05007711A (es) 2005-09-30
US20060264354A1 (en) 2006-11-23
EP1592384A4 (en) 2008-12-31
AU2004206120B2 (en) 2009-09-24
EP1592384B1 (en) 2012-10-31
ES2397836T3 (es) 2013-03-11
PT1592384E (pt) 2013-01-28
WO2004064717A2 (en) 2004-08-05
EP1592384A2 (en) 2005-11-09

Similar Documents

Publication Publication Date Title
CY2013022I1 (el) Συνθεσεις για την θεραπευτικη αγωγη γαστρεντερικων διαταραχων
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
NO20031443L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
IS7099A (is) Efnasambönd til að meðhöndla bólgutruflanir
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
DK1575597T3 (da) Anvendelse af rimexolon til behandling af öjentörhed
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DK1562932T3 (da) 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
NO20053211D0 (no) Forbindelser for behandling av metabolske forstyrrelser.
EP1592384A3 (en) Cop 1 for treatment of inflammatory bowel diseases
DK1448205T3 (da) Kombinationer til behandling af immunoinflammatoriske sygdomme
IS8246A (is) Meðferð á taugahrörnunarástandi
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
DE602004014547D1 (de) Funduskamera
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
NO20054598D0 (no) Beta-karboliner anvendbare for behandling av betennelsessykdommer
EP1611120A4 (en) NEW METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
EP1683468A4 (en) Endoscope